- News
- Announcements
Announcements
Current & archive
Covid-19: HSS/ Horizon Scanning Living Document (v22 June/July2022)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our two new HSO Fact Sheets.
Fact Sheet No. 98 (June 2022)
Selinexor (Nexpovio®) in and dexamethasone for the treatment of multiple myeloma (MM)
Fact Sheet No. 99 (June 2022)
Pembrolizumab (Keytruda) as monotherapy for the adjuvant treatment of stage IIb IIc III melanoma
ATMPs and Gene Therapies in Development. Horizon Scanning – Update 2022
This report is an update of a previous Horizon Scanning report from 2020, which identified 32 ATMPs. Since August 2020, six of these new ATMPs have been approved by the EMA and five more will be decided by 2023. According to market analyses, 535 ATMPs will be investigated in phase 1 to 3 in 2022, with a further 1,451 in preclinical stages. Coagulation factor VIII (haemophilia A) remains the most common target for non-oncology indications and coagulation factor IX (haemophilia B) has risen to become the second most common indication.
To answer the questions, a systematic search of trial registries was conducted to identify gene therapies and ATMPs in development, followed by extraction of data on identified ongoing clinical trials (limited to phase 2/3 and 3), complemented by a search of the EMA database of medicines under assessment to identify those therapies that are close to approval. Published information on the products and the current development/regulatory status was then collected and subsequently converted into short "vignettes".
Publication: Policy Brief No. 006b: https://eprints.aihta.at/1383
Contact: Ozren Sehic
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our six new HSO Fact Sheets.
Fact Sheet No. 92 (May 2022)
Mosunetuzumab (Lunsumio®) Follicular lymphoma
Fact Sheet No. 93 (May 2022)
Capmatinib (Tabrecta®) NSCLC
Fact Sheet No. 94 (May 2022)
Pembrolizumab (Keytruda®) TNBC
Fact Sheet No. 95 (May 2022)
Selpercatinib (Retsevmo®) NSCLC
Fact Sheet No. 96 (May 2022)
Atezolizumab (Tecentriq®) NSCLC
Fact Sheet No. 97 (May 2022)
Axicabtagene ciloleucel (Yescarta®) Follicular lymphoma
Covid-19: HSS/ Horizon Scanning Living Document (v21 April/ May 2022)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our six new HSO Fact Sheets.
Fact Sheet No. 86 (April 2022)
Ciltacabtagene autoleucel (Carvykti®) for the treatment of multiple myeloma (MM)
Fact Sheet No. 87 (April 2022)
Cabozantinib (Cabometyx®) as monotherapy for the treatment of thyroid carcinoma (DTC)
Fact Sheet No. 88 (April 2022)
Tisagenlecleucel (Kymriah®) for the treatment of follicular lymphoma (FL) after two or more lines of systemic therapy
Fact Sheet No. 89 (April 2022)
Polatuzumab vedotin (Polivy®) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of B-cell lymphoma (DLBCL)
Fact Sheet No. 90 (April 2022)
Pembrolizumab (Keytruda®) as monotherapy in adults with colorectal cancer
Fact Sheet No. 91 (April 2022)
Pembrolizumab (Keytruda®) in combination with chemotherapy with or without bevacizumab for cervical cancer
Telemonitoring in Austrian diabetes care: A systematic analysis of evaluation methodologies
The treatment of diabetes mellitus is individually tailored to achieve freedom from symptoms and avoid acute complications and serious secondary diseases. Telemedical diabetes care programs can be supported by digital health applications and may be beneficial to improve diabetes care. This report provides an overview of Austrian telemedicine activities and a systematic review of evaluation methods and evidence of potential health care effects.
Publication: HTA Project Report No. 143: https://eprints.aihta.at/1370/
Contact: Gregor Goetz
Regulation and financing of prenatal screening and diagnostic examinations for fetal anomalies in selected European countries
Prenatal screening and diagnostic tests include First Trimester Screening/Combined Test, non-invasive prenatal test (NIPT), invasive (diagnostic) tests and ultrasound screening for fetal anomalies in the second trimester. Whether and in what form these tests are offered and financed to pregnant women varies considerably between countries. This policy brief provides an overview of country strategies for integrating the tests into antenatal care and their (public) financing in 6 selected European countries (DE, CH, NL, UK, NO, IT).
Publication: Policy Brief No. 12: https://eprints.aihta.at/1369/
Contact: Inanna Reinsperger
CAR-T Cell-Therapies in Development, Update 2022
CAR-T cell-therapies are commonly indicated as „transformative“ therapies referring to the huge expectations associated with them since their market approval in 2017 (USA) and 2018 (Europe). Due to the hope, but also the enormous prices a horizon scanning (HS) document was first published in 2020 to support budget planning in hospitals. In 2020 13 CAR-T cell-therapies in advanced stages were identified. Of these, in addition to Yescarta® and Kymriah®, that were already approved at that time, three further therapies have since been approved by the European Medicines Agency (EMA) between 8/ 2020 and 03/2022: Tecartus® (2020), Abcema® (2021) and Breyanzi® (2022).
This HS document updates the earlier report by surveying the status of the ten therapies already described in 2020 and adding additional therapies that have since then reached a later phase of clinical testing. Within the next year 2023 one new CAR-T cell-Therapy for multiple myeloma will eventually be approved, but further development can be expected with the extension of the approved CAR-T cell-therapies towards earlier lines of therapy and new indications.
Publication: Policy Brief No. 6a, 1. Update: https://eprints.aihta.at/1368
Contakt: Ozren Sehic
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our seven new HSO Fact Sheets.
Fact Sheet No. 79 (March 2022)
Tebentafusp (Kimmtrak®) bei Uveal melanoma
Fact Sheet No. 80 (March 2022)
Relugolix (Orgovyx®) bei Prostate Cancer
Fact Sheet No. 81 (March 2022)
Nivolumab (Opdivo®) bei MIUC
Fact Sheet No. 82 (March 2022)
Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) bei OSCC
Fact Sheet No. 83 (March 2022)
Nivolumab (Opdivo®) + chemotherapy bei OSCC
Fact Sheet No. 84 (March 2022)
Abemaciclib (Verzenios®) bei early breast cancer
Fact Sheet No. 85 (March 2022)
Enfortumab vedotin (Padcev®) Urothelial cancer
